



3 May 2019

ASX ANNOUNCEMENT

ASBrS Releases PREVENT Abstract

Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), today announced that the American Society of Breast Surgeons (ASBrS) issued a press release and the abstract submitted on the interim results of the PREVENT trial.

Particular note should be taken of the expert commentary provided by Dr Julie A. Margenthaler, MD, FACS, Washington University School of Medicine, ASBrS Communications Committee Chair: "Lymphedema represents a significant morbidity for patients who experience it. This study demonstrates that bioimpedance spectroscopy can identify early signs of lymphedema so that interventions can be taken to prevent progression. This is an important step in improving the lives of our breast cancer survivors."

The full manuscript is expected to be published online in the Annals of Surgical Oncology in the coming days. The link to the abstract can be found here:

https://www.breastsurgeons.org/meeting/2019/press_releases/lymphedema

Richard Carreon
Managing Director & CEO

Media Contact:
Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.